Recovery of response to adriamycin and cyclophosphamide by lonidamine in previously treated metastatic breast-cancer patients.

Thirty-one patients with metastatic breast cancer not responding or progressing after initial response to adriamycin + cyclophosphamide (AC) treatment entered a phase 11 study with oral lonidamine in association to AC. Objective clinical responses were observed in 10 patients (32%) and consisted of 1 complete + 9 partial remissions. Disease stability and progression were observed in 8 and 13 cases, respectively. These results were obtained with a marginal toxicity in addition to that already reported for AC therapy, the main additional side effect being myalgia, which was easily manageable in most cases.

Cisplatin (P) versus cyclophosphamide, adriamycin and cisplatin (CAP) for stage III-IV epithelial ovarian carcinoma: a prospective randomized trial.

In 1982 a randomized trial was started to compare a cisplatin-containing polychemotherapy (CAP: cyclophosphamide - CPA 750 mg/m2, adriamycin - ADM 50 mg/m2, cisplatin - P 50 mg/m2 on day 1 every 21 days) with full-dose cisplatin as single agent (P 60 mg/m2/day on days 1 and 2 every 28 days) in 44 patients undergoing exploratory laparotomy or debulking surgery for stage III-IV epithelial ovarian carcinoma with residual disease greater than 5 cm. The response was evaluated at second-look surgery with random biopsies and peritoneal washing. On the basis of the final results the authors underline some data which, although merely indicative (because of the small number of patients) appear to be worth considering since they are in accordance with the latest reports: a) similar response rate (CR + PR = 47%) to first-line treatment in the two groups; b) the CAP treatment may achieve a longer median duration of CRs than the P treatment (20 versus 11 months); c) overall survival seems similar in the two groups of patients (19 versus 18 months), whereas the survival of CRs seems longer in the CAP treated patients (greater than 32 versus 25 months). The authors also discuss some observations on a possible salvage therapy.

[The chordoma. Description of 2 clinical cases and results of oncolytic chemotherapy]. / Il cordoma. Descrizione di due casi clinici e risultati della chemioterapia oncolitica.

Only seven hundred cases of chordoma approximatively are reported in medical literature from 1850 to date. We now describe two cases recently observed at our Medical Division, one of sacro-coccigeal chordoma and the other developed from clivus of Blumenbach. Their peculiarities are briefly discussed and compared with a rapid revision of the literature on this argument. The results of antiblastic therapy are presented and its opportunity in addition to Roentgenologic and surgical therapy is discussed.

[Protective effect of lithium carbonate in neutropenia induced by antiblastic agents and evaluation of its long-term efficacy]. / Effetto protettivo de litio carbonato nella neutropenia da antiblastici e valutazione della sua efficacia a distanza.

The association of lithium carbonate and antiblastic drugs has been studied in 22 patients suffering from tumours to see whether it was able to prevent or attenuate the neutropenising effect and establish whether its protection action on leucocytaemia was not just transitory but was maintained for prolonged treatment also. Patients were submitted to four oncolytic treatment cycles during which administration with LiCO3 was associated with the first and third cycles (LNLN sequence) in 14 patients and with the second and fourth (NLNL sequence) in the other 8. Statistical analysis of the results obtained confirmed that lithium carbonate performs a protective action with respect to antiblastic-induced neutropenia and that the action is long term. The drop in monocytes also seems to diminish after administration of lithium carbonate.

[Cerebral perfusion pressure in endocranial hypertension in comatose head-injured patients]. / Pressione di perfusione cerebrale ed ipertensione endocranica nei traumi cranici in coma.

The aim of the intensive care of the injured is the coupling of the availability and the requirement of the cerebral metabolic substates. The measurement of the cerebral blood flow is not currently available at the bedside and less direct monitoring is required. The cerebral perfusion can be estimated looking at the cerebral perfusion pressure (CPP), that can be easily measured using intracranial pressure (ICP) and the systemic arterial pressure (MAP) monitoring. Hundred-twenty-one consecutive head injured admitted to an Intensive Care Unit were studied assessing the severity of the neurological injury, the CT-Scan diagnosis of the intracranial lesion, the Trauma Score and the behavior of the ICP and MAP. The outcome was classified according to a modified version of the Glasgow Outcome Scale. More than 77% of the patients suffered raised intracranial pressure above 20 mmHg and 16 of them had a CPP less than 60 mmHg for more than 5 minutes. The outcome was directly related to the degree of intracranial hypertension and to the severity of insufficient CPP. The treatment of the severe head injured must be aimed at maintaining a good CPP, because of the close relationships between this value and the prognostic result. The monitoring of the ICP is a reliable and relatively safe procedure in this series, where the rate of infections complicating the intracranial recording is less than 3%.

[Arterio-jugular difference of oxygen and intracranial pressure in comatose, head injured patients. I. Technical aspects and complications]. / Differenza artero-giugulare di ossigeno e pressione intracranica nei traumi cranici in coma. Parte I: Aspetti tecnici e complicanze.

The monitoring of the comatose head injured patients is based on the recording of several data; the intracranial pressure measurements (ICP), associated with the arterial pressure recording, gives a good estimate of the cerebral perfusion pressure (CPP) but further information about the cerebral perfusion are needed. Based on the assumption that the cerebral metabolic rate is kept constant strong relationships exist between the cerebral blood flow (CBF) and the arterovenous difference of oxygen (AVDO2). In order to obtain samples of cerebral venous blood a catheter must be inserted in the internal jugular vein (IJ) with the tip of the cannula reaching the superior jugular bulb. In 224 patients we measured the ICP trough ventricular or subdural catheters; invasive measurement of the arterial pressure was also carried on in all the patients. In 45 patients we measured the AVDO2 and we tested the safety and the reliability of the jugular vein cannulation. During the insertion of the jugular catheters a slight increase of ICP, without any clinical significance, was recorded; in two cases (on a total of 45) accidental carotid puncture occurred. In 9 cases we tested the concordance of the oxygen content between the two IJs; looking at the mean values no statistical difference is detected between the two sides but in some cases relevant differences are recorded. In two cases we inserted the catheters more cranially, reaching a sinus of the cranial basis; the blood collected from these points carries less oxygen that the blood collected in the neck. The rate of infection in this series of ICP monitoring is very low (1.78%) and we had no bleeding at the moment of the insertion of the catheters. Since no significant complications related to the IJ cannulation were recorded we conclude that these techniques are safe and can be easily performed in the clinical setting. Further studies are required in order to investigate the clinical meaning of the differences in the IJs content of oxygen.